---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-182031"
form_type: "8-K"
ticker: "LITS"
cik: "0001262104"
company_name: "Lite Strategy, Inc."
filed_at: "2023-07-05T23:59:59+00:00"
generated_at: "2026-06-13T12:31:52.914814+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ISS recommends MEI Pharma shareholders vote FOR merger with Infinity Pharma

## Summary
- Independent proxy advisory ISS recommends voting FOR the Infinity merger at July 14 special meeting.
- MEI board reiterates support, citing potential to create diversified three-program clinical pipeline.
- Combined company expects key clinical data from both MEI programs by year-end 2023.
- Shareholders of record as of May 24, 2023 are eligible to vote.
- Alliance Advisors is proxy solicitor; Stifel and Morgan Lewis are advisors.

## SEC filing metadata
- accession: 0001193125-23-182031
- form_type: 8-K
- ticker: LITS
- cik: 0001262104
- company_name: Lite Strategy, Inc.
- filed_at: 2023-07-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1262104/000119312523182031/0001193125-23-182031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1262104/000119312523182031/d528523d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-182031
- JSON: https://secwatch.observer/filing/0001193125-23-182031.json
- Plain text: https://secwatch.observer/filing/0001193125-23-182031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.